David A. Cooper

11.2k total citations · 1 hit paper
118 papers, 7.1k citations indexed

About

David A. Cooper is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, David A. Cooper has authored 118 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Infectious Diseases, 83 papers in Virology and 27 papers in Epidemiology. Recurrent topics in David A. Cooper's work include HIV/AIDS drug development and treatment (89 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (53 papers). David A. Cooper is often cited by papers focused on HIV/AIDS drug development and treatment (89 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (53 papers). David A. Cooper collaborates with scholars based in Australia, United States and Thailand. David A. Cooper's co-authors include Andrew Carr, Joep M. A. Lange, Brian Gazzard, Graeme Moyle, Adriano Lazzarin, Bonaventura Clotet, Christine Katlama, Kiat Ruxrungtham, Mark Nelson and Stefano Vella and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

David A. Cooper

115 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adverse effects of antiretroviral therapy

2000 803 citations Andrew Carr, David A. Cooper The Lancet profile →

Peers

David A. Cooper

VIROL

EPIDE

HEPAT

Patrick Yéni France

Gilles Peytavin France

Milos Opravil Switzerland

Keith Henry United States

Jan W. Mulder Netherlands

Graeme Moyle United Kingdom

Mark O. Loveless United States

Kees Brinkman Netherlands

Diane Aschman United States

Kathleen Squires United States

Patrick Yéni France

David A. Cooper

6.8k ×1.2

5.3k ×1.2

VIROL

2.1k ×1.3

EPIDE

1.7k ×1.1

519 ×0.8

HEPAT

Citations per year, relative to David A. Cooper David A. Cooper (= 1×) peers Patrick Yéni

Countries citing papers authored by David A. Cooper

Since Specialization

Citations

This map shows the geographic impact of David A. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Cooper more than expected).

Fields of papers citing papers by David A. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Cooper. The network helps show where David A. Cooper may publish in the future.

Co-authorship network of co-authors of David A. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Cooper. A scholar is included among the top collaborators of David A. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Cooper. David A. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Norman, Jane E., John Norrie, Graeme MacLennan, et al.. (2022). The Arabin Pessary to Prevent Preterm Birth in Women With a Twin Pregnancy and a Short Cervix: The STOPPIT 2 RCT. Obstetrical & Gynecological Survey. 77(1). 1–3. 2 indexed citations

Moore, Cecilia L., Eduardo Gotuzzo, Adeeba Kamarulzaman, et al.. (2016). Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study. AIDS Research and Human Retroviruses. 32(9). 841–850. 12 indexed citations

Amin, Janaki, Mark Boyd, Nagalingeswaran Kumarasamy, et al.. (2015). Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection. PLoS ONE. 10(2). e0118228–e0118228. 31 indexed citations

Elion, Richard, Jean‐Michel Molina, José Ramón Arribas, et al.. (2013). A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 494–497. 33 indexed citations

Kosalaraksa, Pope, Torsak Bunupuradah, Vonthanak Saphonn, et al.. (2012). Prevalence of Anemia and Underlying Iron Status in Naive Antiretroviral Therapy HIV-Infected Children with Moderate Immune Suppression. AIDS Research and Human Retroviruses. 28(12). 1679–1686. 8 indexed citations

Elliott, Julian, Sarah Huffam, Robert Oelrichs, et al.. (2009). Immunopathogenesis and Diagnosis of Tuberculosis and Tuberculosis‐Associated Immune Reconstitution Inflammatory Syndrome during Early Antiretroviral Therapy. The Journal of Infectious Diseases. 200(11). 1736–1745. 86 indexed citations

Lugt, Jasper van der, Sasiwimol Ubolyam, David A. Cooper, et al.. (2008). Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. Journal of Antimicrobial Chemotherapy. 61(5). 1145–1153. 24 indexed citations

Gathe, Joseph, Gerald Pierone, Peter J. Piliero, et al.. (2007). Efficacy And Safety of Three Doses of Tipranavir Boosted with Ritonavir in Treatment-Experienced HIV Type 1-Infected Patients. AIDS Research and Human Retroviruses. 23(2). 216–223. 19 indexed citations

Winston, Alan, Mark Bloch, Andrew Carr, et al.. (2005). Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy. 56(2). 380–387. 42 indexed citations

10.

Sitbon, Olivier, Virginie Gressin, Rudolf Speich, et al.. (2004). Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 170(11). 1212–1217. 180 indexed citations

11.

Mallon, Patrick, John E. Ray, & David A. Cooper. (2003). Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. Journal of Clinical Virology. 26(2). 223–227. 20 indexed citations

12.

Cardiello, Peter, Apicha Mahanontharit, David M. Burger, et al.. (2003). Pharmacokinetics of Once-Daily Saquinavir Hard-Gelatin Capsules and Saquinavir Soft-Gelatin Capsules Boosted With Ritonavir in HIV-1–Infected Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 32(4). 375–379. 31 indexed citations

13.

Kroon, Eugène, Chaiwat Ungsedhapand, Kiat Ruxrungtham, et al.. (2000). A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). AIDS. 14(10). 1349–1356. 17 indexed citations

14.

Pillay, Deenan, Patricia A. Cane, Daina Ratcliffe, Mark Atkins, & David A. Cooper. (2000). Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. AIDS. 14(9). 1111–1116. 37 indexed citations

15.

Carr, Andrew & David A. Cooper. (2000). Adverse effects of antiretroviral therapy. The Lancet. 356(9239). 1423–1430. 803 indexed citations breakdown →

16.

Zaunders, John, Philip Cunningham, Anthony D. Kelleher, et al.. (1999). Potent Antiretroviral Therapy of Primary Human Immunodeficiency Virus Type 1 (HIV‐1) Infection: Partial Normalization of T Lymphocyte Subsets and Limited Reduction of HIV‐1 DNA Despite Clearance of Plasma Viremia. The Journal of Infectious Diseases. 180(2). 320–329. 100 indexed citations

17.

Kaufmann, Gilbert R., Chris Duncombe, Philip Cunningham, et al.. (1998). Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals. AIDS. 12(13). 1625–1630. 43 indexed citations

18.

Cooper, David A., José M. Gatell, Susanne Kroon, et al.. (1993). Zidovudine in Persons with Asymptomatic HIV Infection and CD4+ Cell Counts Greater than 400 per Cubic Millimeter. New England Journal of Medicine. 329(5). 297–303. 161 indexed citations

19.

Lim, Henry W., David A. Cooper, Shigeru Sassa, et al.. (1992). Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia. Journal of the American Academy of Dermatology. 27(2). 287–292. 26 indexed citations

20.

Cooper, David A.. (1979). Der Eingekreiste Wahnsinn. Suhrkamp eBooks. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact